SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- obesity/erectile dysfunction -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (349)10/16/2015 11:28:22 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 435
 
>> Efficacy is not an issue. In phase III testing, toxicity will be a big one, imo. <<

Now that toxicity has raised ugly head..... why did the share trade sharply south for two days before any public disclosure of the death?



To: scaram(o)uche who wrote (349)7/20/2016 1:33:57 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 435
 
Beloranib dropped, zfgn to focus on backup. Don't hold breath.



To: scaram(o)uche who wrote (349)12/28/2017 12:21:46 PM
From: scaram(o)uche  Respond to of 435
 
From William Gerber, and the answer to his question is "no". But it was relatively simple to predict. One of biotech's sad stories, from over-zealous, greedy management.....

pbs.twimg.com